(LPTX) – Company Press Releases
-
Leap Therapeutics Announces $40 Million Private Placement
-
Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
-
Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium
-
Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference
-
Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients
-
Leap Therapeutics to Present New Data from Part A of the DeFianCe Study of DKN-01 Plus Bevacizumab and Chemotherapy in Colorectal Cancer Patients at the 2024 ASCO Gastrointestinal Cancers Symposium
-
Leap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare Conference
-
Leap Therapeutics Reports Third Quarter 2023 Financial Results
-
Leap Therapeutics to Participate at Upcoming Investor Conferences
-
Leap Therapeutics Reports Second Quarter 2023 Financial Results
-
Leap Therapeutics Announces Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer Patients
-
Leap Therapeutics Announces Reverse Stock Split
-
Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting
-
Leap Therapeutics Reports First Quarter 2023 Financial Results
-
Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting
-
Leap Therapeutics Announces Completion of Enrollment in Part A of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients
-
Leap Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
-
Leap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01
-
Leap Therapeutics Acquires Flame Biosciences
-
Leap Therapeutics to Present at B. Riley Securities' 3rd Annual Oncology Conference
-
Leap Therapeutics to Participate at the Piper Sandler 34th Annual Healthcare Conference
-
Leap Therapeutics Reports Third Quarter 2022 Financial Results
-
Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting
-
Leap Therapeutics Announces First Patient Enrolled in DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients
-
Leap Therapeutics Announces First Patient Enrolled in Part C of Phase 2 DisTinGuish Study of DKN-01 in Combination with Tislelizumab for the Treatment of Gastric or Gastroesophageal Junction Cancer
-
Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting
-
Arthur Tzianabos, Ph.D., June Lee, MD FACCP, and Joseph Loscalzo, MD, Ph.D. Join 5AM Ventures
-
Arthur Tzianabos, Ph.D., June Lee, MD FACCP, and Joseph Loscalzo, MD, Ph.D. Join 5AM Ventures
-
Leap Therapeutics to Participate at the Baird 2022 Global Healthcare Conference
-
Leap Therapeutics Announces Appointment of Richard L. Schilsky, MD to its Board of Directors
-
Leap Therapeutics to Present New Data from DisTinGuish Study of DKN-01 Plus Tislelizumab and WAKING Study of DKN-01 Plus Tecentriq® at the ESMO Congress
-
Leap Therapeutics Reports Second Quarter 2022 Financial Results
-
Leap Therapeutics' Board of Directors Member Dr. Monica Bertagnolli Appointed as the Director of the National Cancer Institute
-
Leap Therapeutics Announces Initiation of New DKN-01 Clinical Trials in Gastric Cancer, Colorectal Cancer and Endometrial Cancer
-
Leap Therapeutics to Host Virtual R&D Day on July 12, 2022
-
Leap Therapeutics to Present Initial Data from the Investigator-Sponsored Study of DKN-01 Plus Docetaxel in Patients with Prostate Cancer at the 2022 ASCO Annual Meeting
-
Leap Therapeutics Reports First Quarter 2022 Financial Results
-
Leap Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
-
Leap Therapeutics to Present at Raymond James 43rd Annual Institutional Investors Conference
-
Leica Biosystems and Leap Therapeutics Partner on Companion Diagnostic to Advance Care for Cancer Patients
-
Leap Therapeutics to Present at B. Riley Securities Oncology Investor Conference
-
Leap Therapeutics to Present Positive New Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ASCO GI Cancers Symposium
-
Leap Therapeutics to Present at H.C. Wainwright BioConnect 2022 Conference
-
Leap Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
-
Leap Therapeutics to Participate at the Piper Sandler 33rd Annual Virtual Healthcare Conference
-
Leap Therapeutics Reports Third Quarter 2021 Financial Results
-
Leap Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Leap Therapeutics Announces Pricing of $90 million of Common Stock and Pre-Funded Warrants
-
Leap Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
-
Leap Therapeutics Presents Updated Positive Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ESMO Congress
Back to LPTX Stock Lookup
